PA Capital’s Avalo Therapeutics AVTX Stock Holding History

PA Capital’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6	Closed	-$54K	–	115
2018 Q4	$54K	Buy	+6	New	+$66.9K	0.06%	108

Other funds holding AVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PA Capital's AVTX Position: Q1 2019 in Review

PA Capital sold out of Avalo Therapeutics (AVTX) in Q1 2019, closing a stake of 6 shares — an estimated $54K sold.

PA Capital first reported a position in AVTX in Q4 2018 and held it in 1 quarter. The position peaked at $54K in Q4 2018. 31 funds tracked by Wall St. Rank hold AVTX as of Q1 2019.

PA Capital reported no remaining Avalo Therapeutics position as of Q1 2019 after selling out during the quarter.
PA Capital sold 6 Avalo Therapeutics shares in Q1 2019, an estimated $54K.
PA Capital first reported a position in Avalo Therapeutics in Q4 2018 and held it in 1 quarter.
PA Capital's Avalo Therapeutics position peaked at $54K in Q4 2018.
31 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2019.

Based on PA Capital's 13F filing for Q1 2019, filed 10 May 2019.